Keiichi Fukuda, Founder and CEO of Heartseed Inc., and Professor Emeritus at Keio University, has been awarded the "Japanese Society for Regenerative Medicine Achievement Award" for his exceptional achievements.

This distinguished award is presented to individuals who have made significant scientific, technological advances in the field of regenerative medicine, or have made notable contributions to the development of the Japanese Society for Regenerative Medicine (JSRM). Fukuda has contributed to significant advancements in the field through the development and industrialization efforts of an innovative treatment, "cardiac regenerative therapy", for advanced heart failure.

The award ceremony and lecture were held on March 21, 2024, at the 23rd Annual Meeting of the Japanese Society for Regenerative Medicine in Niigata City. Fukuda delivered a lecture on the basic research and clinical application of cardiac regenerative therapy, and the path towards implementation in society.

A review article of Fukuda's research is scheduled to be published in the English journal "Regenerative Therapy" of JSRM. Through this article, we hope to widely share the potential of cardiac regenerative therapy and our contributions towards its realization.

Since our establishment in 2015, it has been a great honor for Heartseed to support Fukuda's achievements, including the initiation of the Phase 1/2 clinical trial of allogeneic iPSC-derived cardiomyocyte spheroids, HS-001 in Japan (LAPiS trial). Heartseed will continue to lead innovations in the field of regenerative medicine.

About Heartseed

Heartseed Inc. was founded in 2015 to develop and commercialize cardiac remuscularization therapy developed by Professor Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo, Japan. Heartseed has proprietary technologies throughout the entire manufacturing process of the cardiomyocyte-cell product, including purification, cell delivery and iPSC production.

Heartseed announced the global collaboration and license agreement with Novo Nordisk A/S for HS-001 in June 2021. Heartseed received "Minister of Science and Technology Policy Award" at Japan Venture Awards 2021 and "Ministry of Education, Culture, Sports, Science and Technology Award" at Academic Startups 2021, and "Most Promising Pipelines Awards (iPSC)" at Asia Pacific Cell & Gene Therapy Excellence Awards 2022. For more information, visit heartseed.jp, LinkedIn and YouTube.

Company Name: Heartseed Inc.

Established:         November 30, 2015

Founder & CEO:  Keiichi Fukuda

Headquarter:       Seavans South Building 5F, 1-2-3 Shibaura, Minato-ku, Tokyo 105-0023, JAPAN

Contact:

Kikuo Yasui,

COO, Heartseed Inc.

Tel: +81-3-6380-1068

Email: kikuo.yasui@heartseed.jp